Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876)


  • Product name
    Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y]
    See all Caveolin-1 primary antibodies
  • Description
    Rabbit monoclonal [EPR2288Y] to Caveolin-1 (phospho Y14)
  • Specificity
    ab75876 detects Caveolin-1 phosphorylated at tyrosine 14.
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Caveolin-1.
    Database link: Q03135

  • Positive control
    • WB: A673, Insulin treated A673, A673 treated with insulin then the membrane was incubated with phosphatase, HeLa and HeLa cell treated with pervanadate whole cell lysate.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.



Our Abpromise guarantee covers the use of ab75876 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000 - 1/5000. Predicted molecular weight: 20 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway.
    • Tissue specificity
      Expressed in muscle and lung, less so in liver, brain and kidney.
    • Involvement in disease
      Defects in CAV1 are the cause of congenital generalized lipodystrophy type 3 (CGL3) [MIM:612526]; also called Berardinelli-Seip congenital lipodystrophy type 3 (BSCL3). Congenital generalized lipodystrophies are autosomal recessive disorders characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
    • Sequence similarities
      Belongs to the caveolin family.
    • Post-translational
      The initiator methionine for isoform Beta is removed during or just after translation. The new N-terminal amino acid is then N-acetylated.
    • Cellular localization
      Golgi apparatus membrane. Cell membrane. Membrane > caveola. Membrane raft. Colocalized with DPP4 in membrane rafts. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
    • Information by UniProt
    • Database links
    • Alternative names
      • BSCL3 antibody
      • CAV antibody
      • CAV1 antibody
      • CAV1_HUMAN antibody
      • caveolae protein, 22 kD antibody
      • caveolin 1 alpha isoform antibody
      • caveolin 1 beta isoform antibody
      • Caveolin 1 caveolae protein 22kDa antibody
      • Caveolin-1 antibody
      • Caveolin1 antibody
      • cell growth-inhibiting protein 32 antibody
      • CGL3 antibody
      • LCCNS antibody
      • MSTP085 antibody
      • OTTHUMP00000025031 antibody
      • PPH3 antibody
      • VIP 21 antibody
      • VIP21 antibody
      see all

    Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] images

    • All lanes : Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876) at 1/1000 dilution

      Lane 1 : Untreated A673 (Human muscle Ewing's Sarcoma) whole cell lysates
      Lane 2 : A673 (Human muscle Ewing's Sarcoma) treated with insulin, whole cell lysates
      Lane 3 : A673 (Human muscle Ewing's Sarcoma) treated with insulin, whole cell lysates. Then the membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 20 kDa

      Exposure time : 30 seconds

      Blocking/Diluting buffer 5% NFDM/TBST

    • All lanes : Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876) at 1/2000 dilution

      Lane 1 : HeLa cell lysate
      Lane 2 : HeLa cell lysate treated with pervanadate

      Lysates/proteins at 10 µg per lane.

      Goat anti-rabbit HRP at 1/1000 dilution

      Predicted band size : 20 kDa
      Observed band size : 22 kDa (why is the actual band size different from the predicted?)
    • Dot blot analysis of Caveolin-1 (phospho Y14) phospho peptide (Lane 1), Caveolin-1 Non-phospho peptide (Lane 2) labelling Caveolin-1 (phospho Y14) with ab75876 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    References for Anti-Caveolin-1 (phospho Y14) antibody [EPR2288Y] (ab75876)

    ab75876 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab75876.
    Please use the links above to contact us or submit feedback about this product.


    Sign up